Literature DB >> 10591534

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.

H G Xie1, C M Stein, R B Kim, G R Wilkinson, D A Flockhart, A J Wood.   

Abstract

Impaired S-mephenytoin 4'-hydroxylation is a well-described genetic polymorphism affecting drug metabolism in humans. The reported population prevalence of the CYP2C19 poor metabolizer phenotype in Caucasians of European descent has been described as ranging from 0.9% to 7.7%. To address the question of whether the difference in the frequency of poor metabolizers represents an ethnic genetic microheterogeneity in the structure and expression of the CYP2C19 gene in Caucasian individuals, we performed a pooled analysis of available studies. Combined data from the 22 homogeneous studies showed that the frequency of poor metabolizers in healthy unrelated Caucasians determined by phenotyping was 2.8% (110 of 3990; 95% confidence interval 2.3-3.3). Data obtained from eight homogeneous studies that determined the frequency of poor metabolizers by genotyping showed that the genotypic frequency of poor metabolizers was 2.1% (28 of 1356; 95% confidence interval 1.3-2.8), consistent with the poor metabolizer frequency determined by phenotyping. In the extensive metabolizers, 26% (471 of 1786; 95% confidence interval 24.4-28.4) were heterozygotes. The observed frequencies of the three Mendelian genotypes were 73% for wt/wt, 26% for wt/m, and 2.1% for m/m. Based on the overall phenotypic poor metabolizer frequency of 2.8%, the expected genotypic frequencies were 69% for wt/wt, 28% for wt/m and 2.8% for m/m, which are in good agreement to the observed values. However, in the 84 Caucasian phenotyped and genotyped poor metabolizers, approximately 10% of the putative poor metabolizer alleles (17 of 168) were unknown. This study provides a systematic overview of the population distribution of the CYP2C19 poor metabolizer phenotype and CYP2C19 alleles and genotypes in healthy Caucasians living in different geographical areas, and shows a similar polymorphic pattern in the structure and expression of the CYP2C19 gene in the worldwide Caucasian populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591534

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  39 in total

1.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.

Authors:  Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Karin Endrizzi; Renzo Wolbold; Thomas Lang; Andreas Nüssler; Peter Neuhaus; Ulrich M Zanger; Michel Eichelbaum; Thomas E Mürdter
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

2.  Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.

Authors:  Chen-Fang Lin; Li-Jiuan Shen; Fe-Lin Lin Wu; Chyi-Huey Bai; Churn-Shiouh Gau
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 3.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 4.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

5.  Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.

Authors:  Seiji Hokimoto; Tadasuke Chitose; Michio Mizobe; Tomonori Akasaka; Yuichiro Arima; Koichi Kaikita; Satomi Iwashita; Kazunori Morita; Hiroko Miyazaki; Kentaro Oniki; Kunihiko Matsui; Kazuko Nakagawa; Hisao Ogawa
Journal:  Eur J Clin Pharmacol       Date:  2014-04-26       Impact factor: 2.953

Review 6.  The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.

Authors:  T M Bosch; V D Doodeman; P H M Smits; I Meijerman; J H M Schellens; J H Beijnen
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

8.  Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.

Authors:  Ping Liu; Grover Foster; Robert Labadie; Eugene Somoza; Amarnath Sharma
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients.

Authors:  I Rudberg; M Hermann; H Refsum; E Molden
Journal:  Eur J Clin Pharmacol       Date:  2008-08-03       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.